CORESTEMCHEMON Inc (166480) Fair Value & Analysis
Healthcare · KR · Market cap 72.3B KRW
Fair value as of: Jul 7, 2026
From 1 valuation models · updated today
Fair value updated Jul 7, 2026 — revised from 8,837 KRW to 1,316 KRW (−85.1%) since Jun 24, 2026. Share price −29.9% over the past month.
Price vs Fair Value (12 months)
12‑month range 1,060 KRW – 4,800 KRW · fair‑value band 981.90 KRW – 1,964 KRW · the 2,125 KRW price screens above the 1,316 KRW fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
CORESTEMCHEMON Inc (166480) currently trades at 2,125 KRW, while our model-based Fair Value estimate is 1,316 KRW — implying the stock looks roughly 38.1% overvalued today. We read business quality at 23/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 18.4B KRW. Revenue declined 29.0% year over year. It earns a return on equity of -66.1%. Net debt stands at 35.9B KRW. Fundamentals as of Jul 7, 2026
Our scenario range runs from 981.90 KRW (bear case) to 1,964 KRW (bull case); at 2,125 KRW, the current price sits above that range. The share trades about 58% below its 52-week high and 110% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside — at -38%, 166480 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company has a strategic partnership with ATG Lifetech to deliver precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures. The company was formerly known as Corestem, Inc. CORESTEMCHEMON Inc. was founded in 2003 and is based in Seongnam-si, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
CORESTEMCHEMON Inc reported revenue of 20.2B KRW in FY2025 versus 30.2B KRW in FY2021, a compound −9.6%/yr. Reported net income was −26.8B KRW in FY2025.
Is 166480 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.04 | R$46.95 | -10% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$102.95 | A$126.79 | +23% |
| Celltrion, Inc 068270 | 168,500 KRW | 76,943 KRW | -54% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| Moderna, Inc M1RN34 | R$14.75 | R$4.91 | -67% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is CORESTEMCHEMON Inc (166480) undervalued?
What is the fair value of 166480?
What is the quality score of 166480?
What is the revenue of CORESTEMCHEMON Inc (166480)?
What is the net profit margin of 166480?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.